Alcon Laboratories (U.K) Limited

Pentagon Park, Boundary Way, Hemel Hempstead, Hertfordshire, HP2 7UD
Telephone: +44 (0)1442 341 234
Fax: +44 (0)1442 341 200

Summary of Product Characteristics last updated on the eMC: 18/01/2012
SPC Ciloxan 3mg/g Eye Ointment

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 18/01/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 6. 4 - Special Precautions for Storage
Date of revision of text on the SPC:   30-Nov-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Update the storage conditions of the finished product from ‘Do not store above 30°C’ to ‘Do not store above 25°C’.

 

Updated on 20/01/2009 and displayed until 18/01/2012
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   28-Oct-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.1 - 'Ciloxan eye ointment will be indicated for adults and children as follows:
Adults and children 1 year and above' added

Section 4.2 - 'Adults and children 1 year and above' added

Section 4.3 -  Amended to 'Hypersensitivity to the active substance or to any of the excipients. Hypersensitivity to quinolones'

Section 4.4 - Paragraph amended

Section 4.6 - Heading 'Lactation' added

Section 4.8 - New paragraph added after the heading 'Skin Effects'

Section 5.2 - 'There are no pharmacokinetic data available in respect of use in children' added

Section 5.3 - 'The degree of cartilage involvement was found to be dependent on age, specieis and dosage. With 30mg/kg ciprofloxacin in the effect on the joint was minimal.' added

Section 9 - '11/08/2008' added

Section 10 - '28/10/2008' added
Updated on 03/11/2005 and displayed until 20/01/2009
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   ciprofloxacin hydrochloride